On Monday, 27 October 2025, Elicio Therapeutics, Inc. (NASDAQ: ELTX) issued a press release announcing preliminary data from its ongoing Phase 2 AMPLIFY‑7P trial. The report states that 89 patients treated with the ELI‑002 7P vaccine generated robust mKRAS‑specific T‑cell responses, and that these responses were not associated with any particular Human Leukocyte Antigen (HLA) type.
The analysis covered 1,132 unique HLA alleles across primary class I and class II variants, demonstrating that the vaccine’s immunogenicity is independent of HLA diversity. This finding aligns with a recent Cell Reports Methods study that showed 20 out of 20 healthy donors mounted mKRAS‑specific T‑cell responses across diverse HLA backgrounds.
CEO Robert Connelly highlighted that the data support the company’s strategy of an off‑the‑shelf vaccine capable of treating a broad spectrum of pancreatic ductal adenocarcinoma patients. He noted that the ability to elicit strong T‑cell responses in patients with varied HLA types expands the potential market for ELI‑002 7P and reinforces the platform’s promise.
The release marks a significant clinical milestone for Elicio, providing evidence that the AMP technology can overcome a key limitation of many cancer vaccines—HLA restriction. By demonstrating broad applicability, the data strengthen the case for continued development of the Phase 2 program and may enhance investor confidence in the company’s therapeutic strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.